5 completed, 4 active not recruiting, 3 not yet recruiting, 1 recruiting. 8 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Not yet recruiting 3, Active not recruiting 2, Completed 2, Recruiting 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 2 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Longbio Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease LP-005 Injection - Complement-mediated Renal Diseases | Phase 2 | Not yet recruiting | Longbio Pharma | 46 | 2026-02-02 | 2026-01-23 |
| A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) LP-003 Injection, Placebo of LP-003 - Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Not yet recruiting | Longbio Pharma | 150 | 2026-01-20 | 2026-02-06 |
| Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) LP-005 Injection - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Not yet recruiting | Longbio Pharma | 30 | 2025-12-05 | 2025-12-05 |
| A Study of Single Dose of LP-003 in Adolescent Subjects LP-003 Dose 1 (Single), LP-003 Dose 2 (Single) - Allergic Diseases | Phase 1 / Phase 2 | Active not recruiting | Longbio Pharma | 6 | 2025-10-01 | 2026-02-17 |
| Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients LP-003 Injection, Omalizumab, Placebo - Allergic Asthma | Phase 2 | Recruiting | Longbio Pharma | 200 | 2025-01-25 | 2026-01-15 |
| Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients. LP-005 Injection - PNH - Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Active not recruiting | Longbio Pharma | 30 | 2024-11-14 | 2026-01-16 |
| A Study of Single Dose of LP-003 in Healthy Adult Subjects LP-003 200mg, Placebo - Chronic Spontaneous Urticaria | Phase 1 | Active not recruiting | Longbio Pharma | 12 | 2024-10-23 | 2025-12-18 |
| Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis LP-003, Placebo - Seasonal Allergic Rhinitis | Phase 3 | Active not recruiting | Longbio Pharma | 546 | 2024-08-01 | 2025-12-26 |
| Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment LP-003, Placebo, Omalizumab - Chronic Spontaneous Urticaria | Phase 2 | Completed | Longbio Pharma | 202 | 2024-01-26 | 2026-10-21 |
| A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants LP-005 Dose 1 (Single), LP-005 Dose 2 (Single), LP-005 Dose 3 (Single) - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 | Completed | Longbio Pharma | 68 | 2023-11-23 | 2025-12-15 |
| Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult LP-003 dose 1, LP-003 dose 2, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Completed | Longbio Pharma | 180 | 2023-07-06 | 2025-12-15 |
| A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects LP-001 Dose 1 (Single), LP-001 Dose 2 (Single), LP-001 Dose 3 (Single) - Myelodysplastic Syndrome (MDS) | Phase 1 | Completed | Longbio Pharma | 68 | 2022-09-03 | 2025-12-15 |
| A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single) - Chronic Spontaneous Urticaria | Phase 1 | Completed | Longbio Pharma | 60 | 2022-07-13 | 2025-12-12 |
Chronic Urticaria (3) · Hemoglobinuria, Paroxysmal (3) · Rhinitis, Allergic, Seasonal (2) · Myelodysplastic Syndromes (1)
Single Person (4) · Omalizumab (2)
China (13)
Guangsheng He (2) · Huan Zhou (1) · Jieming Qu (1) · Luo Zhang (1) · Minghui Zhao (1) · Xueyan Wang (1) · Xueying Ding (1)